Evaluation of orvepitant in an exploratory open-label clinical study in chronic treatment-refractory cough

Trial Profile

Evaluation of orvepitant in an exploratory open-label clinical study in chronic treatment-refractory cough

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Orvepitant (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Acronyms VOLCANO-1
  • Sponsors NeRRe Therapeutics
  • Most Recent Events

    • 24 May 2017 Primary endpoint (change in objective daytime cough frequency at Week 4 compared to Baseline) has been met, as per the results presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
    • 13 Jun 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top